Free Trial
ASX:IIQ

INOVIQ (IIQ) Stock Price, News & Analysis

About INOVIQ Stock (ASX:IIQ)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$47.40 million
P/E Ratio
N/A
Dividend Yield
15.56%
Price Target
N/A
Consensus Rating
N/A

Company Overview

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was incorporated in 1983 and is headquartered in Notting Hill, Australia.

Receive IIQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INOVIQ and its competitors with MarketBeat's FREE daily newsletter.

IIQ Stock News Headlines

INOVIQ Ltd Expands in Cancer Diagnostics Market
Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
INOVIQ Ltd ShareCafe Hidden Gems Webinar Transcript
IIQ.AX - INOVIQ Ltd
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
ASX:IIQ
CIK
N/A
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$6.55 million
Net Margins
-1,224.84%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.56 million
Price / Cash Flow
N/A
Book Value
A$0.22 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$47.40 million
Optionable
Not Optionable
Beta
2.04
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (ASX:IIQ) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners